An observational study in COVID-19 Pneumonia, Sequelae of; Infection and Respiratory Function Impaired, sponsored by Centro Hospitalar Universitario do Algarve. Active, not recruiting at 2 sites in Portugal. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-29.
Sponsored by Centro Hospitalar Universitario do Algarve · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies in COVID-19 with a site in Portugal — 9 open to participants now, 11 under way, 2 of them phase 3. COVID-19 · Portugal.
Among the 38 studies in COVID-19 with a site in Portugal, this one is the 15th largest by planned enrollment of the 20 observational ones that give a count, is one of 15 that started in 2020, is one of 20 observational ones, reaches primary completion later than 3 of the 10 other live ones, and was the 35th registered.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →9 of the 38 studies in COVID-19 with a site in Portugal are open now. Recruiting first, the newest first:
Faculdade de Motricidade Humana · Sites in Portugal
Ages 18–30 · Healthy volunteers
Pilar Azevedo · Sites in Portugal
Euresist Network GEIE · Sites in Portugal, Germany, Italy and 3 more countries
Ages 18+
Euresist Network GEIE · Sites in Portugal, Germany, Italy and 3 more countries
Ages 18+
Euresist Network GEIE · Sites in Portugal, Germany, Italy and 6 more countries
Ages 18+
A study can be open while its sites in Portugal have not opened yet or have stopped. Only those recruiting at a site in Portugal →
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 10
First in 2016; this study’s year is marked. 15 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 250 is close to the median of 268 across 3,209 observational studies indexed under COVID-19.
Median enrollment 216 across the 17 interventional studies, 699 across the 20 observational. Of the 23 that completed or were terminated, 6 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 38 have an industry lead sponsor. The 10 most frequent:
Centro Hospitalar Universitario do Algarve is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
Centro Hospitalar Universitario do Algarve has 2 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 38 studies in COVID-19 with a site in Portugal, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this prospective multicentric study is to evaluate the presence of long-term pulmonary sequelae in patients who had required hospitalization for treating COVID-19 pneumonia, trough chest CT and pulmonary function tests (PFT).
Secondly we would like to evaluate the possible correlation between the chest CT findings and pulmonary function tests pre-existing co-morbidities and type of therapy used during hospitalization.
The investigators will invite to participate in this study patients who had been hospitalized with positive test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) , namely with positive reverse transcription polymerase chain reaction or positive rapid antigen test, and with respiratory insufficiency (at admission or developed during hospital stay), or with viral pneumonia documented with thorax x-ray or Chest CT, during the period between march 2020 and march 2022.
Patients who agree to participate and sign the informed consent will be enrolled in the study.
Participants will be evaluate in two different periods: approximately 4 to 6 months after hospital discharge and approximately 12 to 14 months after hospital discharge.
The first evaluation includes a physical examination at medical post-COVID-19 consultation, pulmonary function tests and reduced dose chest CT.
The second evaluation includes a physical examination at medical post-COVID-19 consultation, and will include reduced dose chest CT and pulmonary function tests only if there were significative findings on those exams on the first evaluation, or if there are any clinical significative findings at the present moment.
All the evaluations must respect the following time intervals: the pulmonary function tests and the chest CT will be done within a 6 week maximum interval of each other, and both of these examinations will be done within a 8 week maximum interval regarding the clinical evaluation.
Demographic and clinical data will be collected by qualified clinical study staff (i.e., by physicians who conduct the post-COVID-19 medical consultation) and the patient will given the EuroQol 5 Dimension 5 Level questionnaire (EQ-5D-3L) to assess the health status.
The reduced dose Chest CT will be obtained with the patient in a supine position and with breath-holding following inspiration, in a spiral acquisition mode with a 1 ,5 mm slice thickness and the images will be reviewed by four senior radiologist blinded to clinical and respiratory functional tests results.
The pulmonary function tests will be interpreted according to the American Thoracic Society and European Respiratory Society guidelines 2022. The parameters measured included the forced expiratory flow between 25% and 75% of forced vital capacity (FVC), forced expiratory volume (FEV1), FVC/FEV1, vital capacity, total lung capacity, residual volume and the diffusing capacity of lung for carbone monoxide (DLCO), DLCO/Alveolar Volume (AV).
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
This study's planned enrollment of 250 is close to the median of 268 across 3,209 observational studies indexed under COVID-19.
Browse COVID-19 studies →Centro Hospitalar Universitario do Algarve is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
Compared within COVID-19, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →
The study will be conducted in two Portuguese hospitals from the same institution (university center). Patients will be recruited from the follow -up Post-COVID-19 medical consultations. All patients attending these follow- up consultations will be invited to participate and enrolled if they agree to sign the written informed consent (following the ethics committee protocol).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Prevalence of structural lung sequelae after COVID-19 pneumonia
evaluate the presence of lung structural sequelae with chest CT
Time frame: 12 -14 months
Prevalence of functional lung impairment after COVID-19 pneumonia
evaluate the presence of impaired PFT after COVID-19 pneumonia
Time frame: 12 -14 months
Association between chest CT findings and PFT impairment after COVID-19 pneumonia
evaluate the possible correlation between the presence of pulmonary structural alterations on chest CT and the presence of impaired PFT
Time frame: 12-14 months
Prevalence of structural lung sequelae after COVID-19 pneumonia
evaluate the presence of lung structural sequelae with chest CT
Time frame: 4-6 months
Prevalence of functional lung impairment after COVID-19 pneumonia
evaluate the presence of impaired PFT after COVID-19 pneumonia
Time frame: 4-6 months
Association between chest CT findings and PFT impairment after COVID-19 pneumonia
evaluate the possible correlation between the presence of pulmonary structural alterations on chest CT and the presence of impaired PFT
Time frame: 4-6 months
Association between chest CT findings after COVID-19 pneumonia and therapy used during hospitalization
to evaluate if there is any association between the presence of lung structural sequelae on chest CT and the different treatments used during hospitalization (corticotherapy, oxygen therapy, mechanical ventilation)
Time frame: 4-6 months
Association between chest CT findings after COVID-19 pneumonia and therapy used during hospitalization
to evaluate if there is any association between the presence of lung structural sequelae on chest CT and the different treatments used during hospitalization (corticotherapy, oxygen therapy, mechanical ventilation)
Time frame: 12-14 months
Association between chest CT findings after COVID-19 pneumonia and pre-existing co-morbidities
to evaluate if there is any association between the presence of lung structural sequelae on chest CT and pre-existing co-morbidities (diabetes, asthma, hypertension, dyslipidaemia, obesity, chronic obstructive pulmonary disease, cigarette smoking, heart disease and kidney disease)
Time frame: 4-6 months
Association between chest CT findings after COVID-19 pneumonia and pre-existing co-morbidities
to evaluate if there is any association between the presence of lung structural sequelae on chest CT and pre-existing co-morbidities (diabetes, asthma, hypertension, dyslipidaemia, obesity,, chronic obstructive pulmonary disease, cigarette smoking, heart disease and kidney disease)
Time frame: 12 -14 months
Plan to share: Undecided
No publications or documents are linked to this record.
Started Mar 2020 (actual). Primary completion is estimated for Dec 2024, 57 months after the start.
Of 1,640 non-industry observational studies under COVID-19, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 30. This study's planned 57 months is above that.
Counting every sponsor, half of 1,774 studies reached it within 13 months; a quarter within 5 and three quarters within 29.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centro Hospitalar Universitario do Algarve